Bill Haney's latest startup scores deal from Sanofi, its newest Big Pharma partner, with $54M upfront
A heavily financed biotech looking to drug RNA with small molecules is adding yet another company to its Big Pharma shortlist.
Skyhawk Therapeutics, the biotech headed by serial entrepreneur and documentary filmmaker Bill Haney, announced an exclusive, back end-heavy collab deal Tuesday with Sanofi, which will primarily focus on yet-undisclosed targets in both immunology and oncology. Sanofi agreed to pay $54 million upfront, and if all the milestones are reached, that could add up to over $2 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.